Clostridium difficile infection in patients with HIV/AIDS

Current HIV/AIDS Reports

Volumn 10, Issue 3, 2013, Pages 273-282

  Collini, Paul J ^a   Kuijper, Ed ^b   Dockrell, David H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C. difficile infection; Clostridium difficile infection (CDI); Co infections; HIV; HIV AIDS; Immunocompromise

Indexed keywords

COTRIMOXAZOLE; FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOTOXICITY; ENZYME IMMUNOASSAY; FECES MICROFLORA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS;

EID: 84881480471     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0162-z     Document Type: Article

References (99)

1. Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978;75(5):778-82. (Pubitemid 9040959)
2. George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978;1(6114):695. (Pubitemid 8318970)
3. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63-73.
4. Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. 2012 Feb.
5. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107(1):89-95.
6. • Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect. 2013;66(2):115-28. Recent review article of CDI epidemiology including epidemic strains.
7. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435-8. (Pubitemid 351263426)
8. Collini PJ, Bauer M, Kuijper E, et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect. 2012;64(2):131-47.
9. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989-95. (Pubitemid 41817660)
10. Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 2009;30(7):334-43.
11. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol. 2002;51(5):448-54. (Pubitemid 34450603)
12. Shulzhenko N, Morgun A, Hsiao W, et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med. 2011;17(12):1585-93.
13. • Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55. Infectious Disease Society of America (IDSA) guidelines for CDI diagnosis and management 2010.
14. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067-79.
15. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12 Suppl 6:2-18. (Pubitemid 44362038)
16. Crobach MJ, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15(12):1053-66.
17. Robotham J, Wilcox M. Updated Guidance on the Diagnosis and Reporting of Clostridium Difficile. 2012; Available from: http://www.dh.gov.uk/prod-consum- dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-133016.pdf.
18. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1984;6 Suppl 1:S235-41.
19. Bauer MP, Hensgens MP, Miller MA, et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis. 2012;55 Suppl 2:S149-53.
20. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;9:CD004610.
21. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423-7. discussion 7-9.
22. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58(6):403-10.
23. •• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-31. Randomized controlled trial demonstrating efficacy of new drug Fidaxomycin for first episode and recurrent CDI.
24. Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55 Suppl 2:S154-61.
25. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55 Suppl 2:S132-42.
26. Goldstein EJ, Citron DM, Sears P, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother. 2011;55(11):5194-9.
27. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
28. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922-31.
29. Guo B, Harstall C, Louie T, et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther. 2012;35(8):865-75.
30. •• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15. First randomized controlled trial of fecal microbiota transplantation demonstrating its efficacy for treating recurrent CDI.
31. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012;40(6):643-8.
32. Hota S. Oral vancomycin followed by fecal transplant versus tapering oral vancomycin. clincaltrials.gov; 2010 [18 December 2012]; Available from: http://clinicaltrials.gov/ct2/show/NCT01226992 ].
33. ••Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197-205. Randomized control trial demonstrating the efficacy of monoclonal antibodies against C. difficile toxins as an adjunct to antimicrobial agents for reducing recurrence.
34. Mastroianni A, Coronado O, Nanetti A, et al. Nosocomial Clostridium difficile-associated diarrhea in patients with AIDS: a three-year survey and review. Clin Infect Dis. 1997;25 Suppl 2:S204-5.
35. Zulu I, Kelly P, Mwansa J, et al. Contrasting incidence of Clostridium difficile and other enteropathogens in AIDS patients in London and Lusaka. Trans R Soc Trop Med Hyg. 2000;94(2):167-8. (Pubitemid 30307285)
36. Mathewson JJ, Salameh BM, DuPont HL, et al. HEp-2 cell-adherent Escherichia coli and intestinal secretory immune response to human immunodeficiency virus (HIV) in outpatients with HIV-associated diarrhea. Clin Diagn Lab Immunol. 1998;5(1):87-90. (Pubitemid 28062953)
37. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control. 2000;28(3):262-6. (Pubitemid 30397524)
38. Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005;41(11):1621-7. (Pubitemid 41691601)
39. Pulvirenti J, Mehra T, Hafiz I, et al. Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. Diagn Microbiol Infect Dis. 2002;44(4):325-30. (Pubitemid 36120709)
40. Gordon MA, Kankwatira AM, Mwafulirwa G, et al. Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: an emerging disease pathogenesis. Clin Infect Dis. 2010;50(7):953-62.
41. Larsen IK, Gradel KO, Helms M, et al. Non-typhoidal Salmonella and Campylobacter infections among HIV-positive patients in Denmark. Scand J Infect Dis. 2011;43(1):3-7.
42. Barbut F, Meynard JL, Guiguet M, et al. Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(3):176-81.
43. Hutin Y, Molina JM, Casin I, et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS. 1993;7(11):1441-7. (Pubitemid 23333832)
44. Tumbarello M, Tacconelli E, Leone F, et al. Clostridium difficile-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. Eur J Gastroenterol Hepatol. 1995;7(3):259-63.
45. Bouza E, Padilla B, Catalan P, et al. Diarrhea associated with Clostridium difficile: one-year experience in a general hospital. Rev Clin Esp. 1996;196(7):424-30. (Pubitemid 26248046)
46. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363-72. (Pubitemid 34183887)
47. Mody LR, Smith SM, Dever LL. Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Infect Control Hosp Epidemiol. 2001;22(1):42-5. (Pubitemid 32065154)
48. Buchner AM, Sonnenberg A. Medical diagnoses and procedures associated with clostridium difficile colitis. Am J Gastroenterol. 2001;96(3):766-72. (Pubitemid 32240728)
49. Saddi VR, Glatt AE. Clostridium difficile-associated diarrhea in patients with HIV: a 4-year survey. J Acquir Immune Defic Syndr. 2002;31(5):542-3. (Pubitemid 35448663)
50. Sherer R, Pulvirenti J, Stieglitz K, et al. Hospitalization in HIV in Chicago. J Int Assoc Physicians AIDS Care (Chic). 2002;1(1):26-33.
51. Palella Jr FJ, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16(12):1617-26. (Pubitemid 34921107)
52. Pavie J, Menotti J, Porcher R, et al. Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era. Int J Infect Dis. 2012;16(9):e677-9.
53. Samie A, Obi CL, Franasiak J, et al. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. AmJTrop Med Hyg. 2008;78(4):577-85. (Pubitemid 351845160)
54. Willingham FF, Ticona Chavez E, Taylor DN, et al. Diarrhea and Clostridium difficile infection in Latin American patients with AIDS. Working Group on AIDS in Peru. Clin Infect Dis. 1998;27(3):487-93. (Pubitemid 28421995)
55. Onwueme K, Fadairo Y, Idoko L, et al. High prevalence of toxinogenic Clostridium difficile in Nigerian adult HIV patients. Trans R Soc Trop Med Hyg. 2011;105(11):667-9.
56. Jha AK, Uppal B, Chadha S, et al. Clinical and Microbiological Profile of HIV/AIDS Cases with Diarrhea in North India. J Pathog. 2012;2012:971958.
57. Cappell MS, Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. Am J Gastroenterol. 1993;88(6):891-7. (Pubitemid 23181876)
58. Lu SS, Schwartz JM, Simon DM, et al. Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol. 1994;89(8):1226-9. (Pubitemid 24245800)
59. Zuckerman E, Kanel G, Ha C, et al. Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterology. 1997;112(3):991-4. (Pubitemid 27113826)
60. Beaugerie L, Ngo Y, Goujard F, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology. 1994;107(3):858-63. (Pubitemid 24265536)
61. DeMarais PL, Gertzen J, Weinstein RA. Nosocomial infections in human immunodeficiency virus-infected patients in a long-term-care setting. Clin Infect Dis. 1997;25(5):1230-2. (Pubitemid 27513213)
62. Olofinlade O, Chiang C. Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol. 2001;32(1):82-4. (Pubitemid 32038119)
63. Younus F, Steigbigel RT. Images in clinical medicine. Nodular Clostridium difficile colitis. N Engl J Med. 2004;350(10):e9.
64. Cozart JC, Kalangi SS, Clench MH, et al. Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment. J Clin Gastroenterol. 1993;16(3):192-4. (Pubitemid 23106882)
65. Pepin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007;102(12):2781-8. (Pubitemid 350179349)
66. Alonso R, Gros S, Pelaez T, et al. Molecular analysis of relapse vs re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J Hosp Infect. 2001;48(2):86-92. (Pubitemid 32700706)
67. Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007;142(7):624-31. discussion 31. (Pubitemid 47080440)
68. • Saxena D, Li Y, Yang L, et al. Human microbiome and HIV/AIDS. Curr HIV/AIDS Rep. 2012;9(1):44-51. Review article summarizing what is known about the effect of HIV on the microbiome.
69. Qiao X, He B, Chiu A, et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006;7(3):302-10.
70. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1(2):101-14. (Pubitemid 33586045)
71. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1(8648):1156-60. (Pubitemid 19138849)
72. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46(2):757-8. (Pubitemid 351231331)
73. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr. 2011;57(5):363-70.
74. th Conference on Retroviruses and Opportunistic Infections. Seattle; 2012; Available from: http://www.retroconference.org/2012b/ Abstracts/43386.htm. Accessed 31 Mar 2013.
75. Mainardi JL, Lacassin F, Guilloy Y, et al. Low rate of Clostridium difficile colonization in ambulatory and hospitalized HIV-infected patients in a hospital unit: a prospective survey. J Infect. 1998;37(2):108-11. (Pubitemid 28482911)
76. Hutin Y, Casin I, Lesprit P, et al. Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward. Clin Infect Dis. 1997;24(5):920-4. (Pubitemid 27193878)
77. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect. 2001;7(8):421-7. (Pubitemid 34960333)
78. Epple HJ, Zeitz M. HIV infection and the intestinal mucosal barrier. Ann N Y Acad Sci. 2012;1258:19-24.
79. Varin A, Manna SK, Quivy V, et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem. 2003;278(4):2219-27. (Pubitemid 36801289)
80. Vilhardt F, Plastre O, Sawada M, et al. The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem. 2002;277(44):42136-43. (Pubitemid 35257530)
81. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983;148(1):93-100. (Pubitemid 13039317)
82. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342(6):390-7. (Pubitemid 30084537)
83. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA. 2001;98(18):10362-7. (Pubitemid 32803025)
84. Ryan A, Lynch M, Smith SM, et al. A Role for TLR4 in Clostridium difficile Infection and the Recognition of Surface Layer Proteins. PLoS Pathog. 2011;7(6):e1002076.
85. Modi N, Gulati N, Solomon K, et al. Differential binding and internalization of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand J Immunol. 2011;74(3):264-71.
86. Mahida YR, Galvin A, Makh S, et al. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun. 1998;66(11):5462-9. (Pubitemid 29044645)
87. Dockrell DH. The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clin Microbiol Infect. 2003;9(8):766-79. (Pubitemid 37121078)
88. Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742-8.
89. Dockrell DH, Edwards S, Fisher M, et al. Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals. J Infect. 2011;63(3):177-86.
90. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998;41(Suppl C):21-7. (Pubitemid 28230296)
91. Reiss P. HIV, co-morbidity and ageing. J Int AIDS Soc. 2012;15 Suppl 4:18073.
92. Terhes G, Urban E, Soki J, et al. Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol. 2004;42(9):4316-8. (Pubitemid 39296165)
93. Astellas Pharma Ltd. Dificlir (fidaxomicin). Summary of product characteristics. 2012; Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002087/WC500119705.pdf. Accessed 31 Mar 2013.
94. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-9.
95. Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent clostridium difficile infection. Case Rep Infect Dis. 2012;2012:810943.
96. Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6):E161-5.
97. Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118(13):3499-503.
98. Foglia G, Shah S, Luxemburger C, et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30(29):4307-9.
99. Geretti AM, Brook G, Cameron C, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9(10):795-848.